Virginia Drug Board: Using Medicare to Lower Prescription Costs

As prescription drug costs continue to strain household budgets across the United States, Virginia lawmakers are advancing a novel approach to affordability: a state-level prescription drug affordability board designed to leverage Medicare’s negotiating power. The initiative, gaining momentum in the state legislature, aims to move further than similar efforts in other states by directly mirroring the drugs selected for price negotiation by the federal Medicare program.

The core idea is to establish an annual list of drugs, identical to those chosen by Medicare for price negotiations, and then set upper payment limits – essentially a price ceiling – for those medications within Virginia. This strategy, proponents argue, will streamline the process and maximize impact, avoiding the lengthy and complex individual assessments undertaken by many other state-level boards. Currently, nine other states have established prescription drug affordability boards, but only four possess the authority to set such upper payment limits, and none are explicitly aligning their targets with Medicare’s selections.

How Virginia’s Plan Differs

Most existing state affordability boards begin by independently identifying drugs deemed excessively expensive within their borders. This process involves data collection, expert review, and often, public hearings. Virginia’s approach, by contrast, would essentially adopt Medicare’s list as a starting point, significantly reducing the administrative burden and accelerating the timeline for potential cost reductions. This alignment with Medicare is seen as a key advantage, as it taps into the substantial analytical resources and negotiating leverage already employed by the federal government.

The move comes as Medicare itself begins to exercise its newly granted authority to negotiate drug prices, a provision of the Inflation Reduction Act passed in 2022. Medicare Part D, which helps cover prescription drug costs for people with Medicare, offers a variety of plans, with nine different options available in Virginia for 2026, according to Medicare.org. These plans range from basic options with lower premiums but higher out-of-pocket costs to enhanced plans with more comprehensive coverage.

The Role of Medicare and Virginia’s Retirees

For Virginia residents enrolled in Medicare, understanding their prescription drug coverage is crucial. The state’s Medicare-coordinating plan, administered by Anthem Blue Cross and Blue Shield, includes prescription drug benefits managed by Express Scripts. A recent memo from the Virginia Department of Human Resource Management details these benefits for state retirees, highlighting that the drug benefit is considered an enhanced Medicare Part D plan. This means it offers additional coverage beyond the standard Medicare Part D benefits.

The proposed state board’s actions would not directly alter Medicare benefits for those enrolled in the federal program. Instead, it would focus on regulating drug prices within the state’s broader healthcare system, potentially impacting costs for individuals with private insurance, as well as those paying cash prices for medications.

What are Prescription Drug Affordability Boards?

Prescription drug affordability boards are state-level entities tasked with examining the costs of prescription drugs and implementing strategies to lower those costs for residents. These boards typically have the authority to conduct investigations, collect data from pharmaceutical companies, and recommend policies to state lawmakers. The specific powers and functions of these boards vary significantly from state to state.

The effectiveness of these boards is still being evaluated. A key challenge is balancing the goal of affordability with the need to ensure continued pharmaceutical innovation. Setting excessively low price ceilings could discourage companies from investing in research and development of new drugs.

Potential Impact and Remaining Questions

If implemented, Virginia’s approach could have several significant effects. It could lead to lower prescription drug prices for a wider range of consumers, potentially saving individuals and the state money. It could as well create a model for other states seeking to address drug affordability, offering a streamlined and efficient alternative to the more complex approaches currently being pursued.

However, several questions remain. The legal authority of the board to set upper payment limits could be challenged by pharmaceutical companies. The board will also need to navigate the complexities of the pharmaceutical supply chain and consider the potential impact of its actions on drug availability. The success of the board will depend on its ability to effectively enforce its regulations and ensure compliance from pharmacies and other stakeholders.

The details of how the board will operate, including its membership, funding, and specific procedures, are still being worked out by state lawmakers. The legislation is currently under consideration and is subject to further debate and amendment.

What comes next: The Virginia General Assembly will continue to debate and refine the legislation establishing the prescription drug affordability board. If passed, the board will be established and begin its work of identifying drugs and setting upper payment limits, with the first regulations potentially taking effect in 2027. Ongoing monitoring of the board’s activities and its impact on drug prices will be crucial to assess the effectiveness of this innovative approach.